Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Recommendation of “Hold” by Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has been given an average rating of “Hold” by the five analysts that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $27.84.

Separately, StockNews.com began coverage on shares of Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Cara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CARA. XTX Topco Ltd bought a new stake in Cara Therapeutics during the 3rd quarter worth about $29,000. FMR LLC lifted its position in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Curi RMB Capital LLC acquired a new position in Cara Therapeutics during the 4th quarter valued at about $277,000. Shay Capital LLC acquired a new position in Cara Therapeutics during the 4th quarter valued at about $524,000. Finally, Rockefeller Capital Management L.P. acquired a new position in Cara Therapeutics during the 4th quarter valued at about $953,000. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Stock Performance

CARA opened at $4.97 on Tuesday. The firm’s 50-day simple moving average is $4.94 and its 200-day simple moving average is $4.07. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $13.80. The firm has a market cap of $22.71 million, a price-to-earnings ratio of -0.24 and a beta of 0.50.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.